MedPath

First Patient Dosed in Marengo's Invikafusp Alfa Trial Expansion to Europe

Marengo Therapeutics has dosed the first patient in its European expansion of the invikafusp alfa trial, marking a significant step in oncology research. This development is part of a broader trend in first-in-human (FIH) clinical trials, with oncology leading as the largest therapy area.

According to GlobalData's 'Clinical Trial Descriptors Trends Insight Report Overview' report, oncology was the largest therapy area within FIH trials as of September 2023. Following oncology, infectious diseases and the central nervous system were also significant areas of focus for some trials. The GlobalData clinical trial database highlights that there are 1,540 ongoing FIH clinical trials in oncology across 3,359 sites at the time of writing.
This expansion of Marengo's invikafusp alfa trial into Europe represents a pivotal moment in the ongoing research and development efforts within the oncology sector. The dosing of the first patient in this expanded trial phase underscores the commitment to advancing therapeutic options for patients battling cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Gliofocus Study Expands Globally to Evaluate Niraparib in Glioblastoma

The Gliofocus Study, a Phase 3 trial, has expanded to new sites in Europe and the U.S. to assess niraparib versus temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.

Breakthroughs in Clinical Trials: A Week of Promising Developments

This week's clinical trials round-up highlights significant advancements in treatments for various conditions, including idiopathic pulmonary fibrosis, diabetes, COPD, and advanced solid tumours. Key developments include positive Phase 2 results for Faron Pharmaceuticals' BEXMAB trial, AstraZeneca's Phase 2a COURSE trial for COPD, and Johnson & Johnson's Phase 3 QUASAR maintenance study for ulcerative colitis.

Marengo Therapeutics Advances Invikafusp Alfa into Phase 2 for PD-1 Resistant Tumors, Expands Trial to Europe

Marengo Therapeutics has dosed the first patient in the Phase 2 portion of the STARt-001 trial, evaluating invikafusp alfa in advanced anti-PD-1 resistant solid tumors.

Sinovac Launches Phase III Trial of Bivalent HFMD Vaccine

Sinovac Biotech has initiated a Phase III clinical trial for its bivalent vaccine targeting Hand Foot and Mouth Disease (HFMD).

Targeted Alpha Therapy Shows Promise in Expanding Cancer Treatment Landscape

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-IPF Trial for Idiopathic Pulmonary Fibrosis

Nerandomilast met the primary endpoint in the FIBRONEER-IPF trial, demonstrating a statistically significant absolute change from baseline in Forced Vital Capacity (FVC) at week 52 compared to placebo.

Bicara, Zenas, and MBX Bio Launch IPOs, Raising $703M for Clinical Trials

Bicara Therapeutics raised $315 million to fund a pivotal trial of ficerafusp alfa for head and neck squamous cell carcinoma (HNSCC).

Gilead's Lenacapavir Achieves 100% Efficacy in HIV Prevention Trial

Gilead Sciences' lenacapavir, a twice-yearly injectable medication, demonstrated 100% efficacy in preventing HIV among cisgender women in Phase 3 trials.

Greenwich LifeSciences' Flamingo-01 Trial Expands into Europe and Broadens Patient Enrollment

Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.

Spectral Medical Expands Tigris Trial for PMX Hemoperfusion Device in Septic Shock

Spectral Medical has added three new clinical trial sites for its Phase III Tigris trial, evaluating the PMX hemoperfusion device for septic shock and endotoxemia.

Reference News

[1]
First patient dosed as Marengo's invikafusp alfa trial expands to Europe
finance.yahoo.com · Dec 23, 2024

Oncology leads as the largest therapy area in FIH trials, with 1,540 ongoing trials across 3,359 sites, followed by infe...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy